Beijing Eryosyn Biotech Secures Tens of Millions in Pre-A Funding to Accelerate Exosome Technology Development

Recently,Beijing ERXY Technology Co., Ltd. (hereinafter referred to as “ERXY”) announced the successful completion of its Pre-A financing round, raising tens of millions of yuan. The round was exclusively led by the well-known investment firm Sanze Venture Capital.This significant milestone not only injects new vitality into the company’s sustained development, but also marks broad market recognition of ERXY’s profound expertise and promising prospects in the field of exosome technology.

Since its establishment in 2021, ERXY has remained dedicated to the research, development, and application of exosome-related technologies, striving to advance the life and health sector through technological innovation. Upholding its corporate vision of “Advancing Exosome Applications to Safeguard Life and Health,” the company has leveraged its technical expertise and product innovation capabilities to successfully establish a leading domestic platform for exosome-related targeted enrichment and application technologies, making significant contributions to technological progress and industrial upgrading within the industry.

The successful completion of this Pre-A financing round provides strong financial support for the future development of ERXY. It is reported that the funds raised will be primarily allocated to the translational development of exosome-based diagnostic products, the expansion of the exosome targeted enrichment platform, market expansion, and team building.

In terms of product R&D, ERXY plans to further strengthen technological innovation and launch more competitive exosome diagnostic products to meet the growing market demand. Meanwhile, the company will also expand the application scope of its exosome targeted enrichment platform to enhance its efficacy in disease diagnosis and treatment.

In terms of market expansion, ERXY will actively seek cooperation opportunities with outstanding domestic and international enterprises to jointly promote the widespread application and industrialization of exosome technology. Through close collaboration with partners, the company will continuously expand its market share and enhance its brand influence.

Since its establishment three years ago, ERXY has achieved rapid development with the support of angel-round financing from Yuansheng Venture Capital. The company has successfully built a brain-derived exosome targeted enrichment platform. Leveraging this innovative technological platform, ERXY has entered into a strategic collaboration with Xuanwu Hospital and successfully secured funding for the “Youcu Plan” project initiated by the Beijing Municipal Health Commission. Furthermore, the company’s first targeted exosome Class II in vitro diagnostic reagent product has successfully passed the qualification review for Beijing’s Innovative Medical Device Program. With priority support under the innovation pathway, the company is now rapidly advancing registration-related clinical trials and other associated work.

Regarding the successful completion of this Pre-A round financing,Company Founder: Ma Yongxiangstated: “We sincerely appreciate the trust and support shown by Sunz Investment in ERXY. The success of this financing round will inject strong momentum into the company’s future development, accelerating product translation and R&D efforts, while further enriching our product portfolio. We also extend our heartfelt gratitude to our existing shareholder, Yuansheng Venture Capital, for their steadfast support. Their involvement has enabled significant progress in our product development and corporate management, leading to rapid breakthroughs in the field of targeted exosome enrichment. We will continue to adhere to a market-demand-oriented approach, promoting the practical application of targeted exosome technology in diagnostics and therapeutics, thereby making greater contributions to human health.”

Investor in this round: Sunz Venture Capital“It stated: ‘In an era of accelerating population aging, the diagnosis and treatment of neurodegenerative diseases have garnered increasing attention, with Alzheimer’s disease and Parkinson’s disease being the primary focus. Precision diagnosis and treatment for these two major conditions represent the future direction of development. ERXY has mastered core technologies in exosome extraction, purification, and diagnostic detection through years of accumulated clinical research, positioning itself at the forefront of the industry. Its core team possesses extensive experience in the R&D and marketing of life sciences and in vitro diagnostics (IVD), with highly prominent professional expertise and complementary skills, forming a pragmatic team capable of achieving success. We are very optimistic about the company’s future growth and development.’”

Looking ahead, ERXY will continue to uphold its corporate vision of “dedicating itself to exosome applications and serving as a guardian of life and health,” while continuously strengthening technological innovation and product R&D capabilities to enhance core competitiveness. Meanwhile, the company will actively expand market channels and seek more partners to jointly promote the popularization and development of exosome technology, contributing greater strength to the cause of human life and health.